Search
Now showing items 1-10 of 42
The s100 proteins as mediators of inflammation are increased in myeloproliferative neoplasm and downregulated by jak2 inhibition
(Ferrata Storti Foundation, Pavia, 2016)
S100a8/9 activation of mapk pathway is supported by its receptors rage and tlr4 in polycythemia vera
(Ferrata Storti Foundation, Pavia, 2017)
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
(Amer Soc Hematology, Washington, 2008)
Hydroxyurea, a drug widely used for treating myeloproliferative diseases, has also been approved for the treatment of sickle cell disease by raising fetal hemoglobin (HbF). We have shown that nitric oxide (NO) and the ...
Expression analysis of jak-stat dependent s100 calcium binding proteins a4 and a12 in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2013)
Oxidative stress in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2014)
A prognostic model to predict thrombosis in essential thrombocythemia
(Ferrata Storti Foundation, Pavia, 2014)
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
(Amer Soc Hematology, Washington, 2019)
Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative ...
Cd38 and interleukin 6 gene polymorphism in b-cell chronic lymphocytic leukemia-correlation with clinical and laboratory parametars
(Ferrata Storti Foundation, Pavia, 2016)